Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50. The guideline changes by the U.S. Preventive Read more…
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs. In comparison to what is already known about specific mutations that drive early-stage cancer growth – Read more…
An artificial intelligence (AI) program accurately predicts the risk that lung nodules detected on screening CT will become cancerous, according to a study published in the journal Radiology. Lung cancer is the leading cause of cancer death worldwide, with an estimated 1.8 million deaths in 2020, according to the World Health Read more…
Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome — including 6.3% of those with Lynch syndrome — could have their conditions remain undetected with current universal tumor-screening methods, and at least 7.1% of people with colorectal cancer have an identifiable inherited genetic mutation, according to new Read more…
In a study conducted by Dr Romain Palich of the Medical Oncology department, Pitié-Salpêtrière hospital in Paris, France and colleagues almost half patients with cancer showed no anti-spike antibody response after a first injection of BNT162b2 (Pfizer-BioNTech) vaccine, and this low seroconversion rate was much worse in elderly patients and in Read more…
For cancer patients, the road from diagnosis to survivorship feels like a never-ending parade of medical appointments: surgeries, bloodwork, chemotherapy, radiation treatments, scans. The routine is time-consuming and costly. So, when hospitals charge patients double-digit parking fees, patients often leave the garage demoralized. Iram Leon vividly remembers the first time Read more…
Astellas’ ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers TOKYO, May 17, 2021 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Read more…
Cardioprotective drugs during adjuvant therapy for early-stage breast cancer do not protect against long-term decline in cardiac function, according to new data from the PRADA trial presented May 16 during ACC.21 and simultaneously published in Circulation. In the single center, double-blind trial, Siri Lagethon Heck, MD, PhD, et al., assessed the long-term impact of candesartan cilexetil Read more…
In a recent study, researchers at Fox Chase Cancer Center found that there are major limitations in using cystoscopy for predicting the presence of muscle-invasive bladder cancer in patients who are candidates for bladder removal. A cystoscopy is an endoscopic procedure that allows surgeons to examine the lining of the Read more…
Treatment guided by molecular imaging technology invented and developed by researchers at Winship Cancer Institute of Emory University shows improved disease-free survival rates for men who have undergone surgical removal of their prostate, according to findings published in the medical journal The Lancet. The randomized trial enrolled 165 patients whose cancer recurred Read more…